Top Abstract Purchase Related
Home
>
Node
>
Subnode

Vaccination and gene therapy with naked DNA

Mölling, K.

Zeitschrift für Arztliche Fortbildung und Qualitatssicherung 92(10): 681-683

1998

ISSN/ISBN: 1431-7621
PMID: 10028596
Document Number: 491821
After injection into the organism, naked DNA causes a slight protein expression. A vaccination is possible, if the DNA encodes for viral or tumor antigens. The DNA proved to be a successful vaccine against virus as well as carcinoma in small animals and safe in humans. However, efficiency has to be increased in the latter. Therefore, combinations of different substances are currently under investigation. Naked DNA is also suitable for gene replacement or gene medicine. However, this is possible only if lowest amounts of proteins cause a biologic effect as done by cytokines, growth hormones etc. DNA is a cheap option for vaccination and treatment, it is easy to transport and therefore of interest for third world countries.

Document emailed within 1 workday
Secure & encrypted payments

Nomura, T.; Nakajima, S.; Kawabata, K.; Yamashita, F.; Takakura, Y.; Hashida, M. 1997: Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer Cancer Research 57(13): 2681-2686
Tong, X.W.; Engehausen, D.G.; Kaufman, R.H.; Agoulnik, I.; Contant, C.; Freund, C.T.; Oehler, M.K.; Kim, T.E.; Hasenburg, A.; Woo, S.L.; Kieback, D.G. 1998: Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy Anticancer Research 18(2a): 713-718
Neve, R.L.; Geller, A.I. 1995: A defective herpes simplex virus vector system for gene delivery into the brain: comparison with alternative gene delivery systems and usefulness for gene therapy Clinical Neuroscience 3(5): 262-267
Soriano, F.; Ponte, C. 1992: Being able to have a "Maspacbus-V," why settle for less? or the emperor is naked Enfermedades Infecciosas y Microbiologia Clinica 10(8): 441-444
Khan, K.A.; Goravalingappa, J.P. 1982: Naked megakaryocyte nuclei--a clue to malignancy Indian Journal of Cancer 19(1): 62-64
Yoon, S.J.; Heo, D.S.; Kang, J.O.; Kim, N.K. 1999: Combination gene therapy of IL-12 and allogeneic MHC class i gene via stimulating NK cytolytic activity Anticancer Research 19(5b): 4337-4342
Guo, M.-g.; Jiang, M.-h.; Yang, Q.; Li, Y.-m.; Cui, Z.-f.; Li, L.-f.; Wu, M.-c.; Qian, Q.-j. 2004: Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene Zhonghua Yi Xue Za Zhi 84(14): 1147-1151
Grgić, M. 2000: Gene therapy of tumors of the head and neck: clinical use of the p53 tumor suppressor gene Lijecnicki Vjesnik 122(1-2): 14-16
Bubeník, J.; Zeuthen, J.; Bubeníková, D.; Símová, J.; Jandlová, T. 1993: Gene therapy of cancer: use of IL-2 gene transfer and kinetics of local T and NK cell subsets Anticancer Research 13(5a): 1457-1460
Bellon, G. 1998: From gene transfer to gene therapy in cystic fibrosis, how long is the road? La Revue du Praticien 48(1): 5-8
Cooper, M.J. 1996: Noninfectious gene transfer and expression systems for cancer gene therapy Seminars in Oncology 23(1): 172-187
Kaneda, Y.; Morishita, R. 1997: Development of in vivo gene transfer methods towards future gene therapy Rinsho Byori. Japanese Journal of Clinical Pathology 45(2): 99-105
Zentilin, L.; Tafuro, S.; Serra, C.; Falaschi, A.; Giacca, M. 1998: Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells Annali Dell'istituto Superiore di Sanita 34(4): 447-455
Sun, X.-Y.; Wu, Z.-D.; Hu, J.-B. 2002: Suicide gene therapy of hepatocellular carcinoma and delivery procedure and route of therapeutic gene in vivo Hepatobiliary and Pancreatic Diseases International: Hbpd Int 1(3): 373-377
Huang, X.; Cao, X.; Zhang, W. 1998: Enhanced antitumor effect of suicide gene therapy by SCF, GM-CSF gene transfer in vivo and its immunological mechanism Zhonghua Zhong Liu Za Zhi 20(4): 270-273
Zhao, M.; Xiao, S.-w.; Yang, J.-x.; Zhang, S.-w.; Lü, Y.-y. 2005: Detection of p53 gene change and serum antibody level in phase Ii clinical trial of ad p53 gene therapy Zhonghua Yi Xue Za Zhi 85(49): 3495-3498
Huff, B. 2003: Gene genie. can gene therapy deliver a better fusion blocker? Gmhc Treatment Issues: the Gay Men's Health Crisis Newsletter of Experimental Aids Therapies 17(12): 7
Caplan, A.I.; Mosca, J.D. 2000: Orthopaedic gene therapy. Stem cells for gene delivery Clinical Orthopaedics and Related Research 2000(379(Suppl): S98-100
Tamiya, T.; Ohmoto, T.; Wei, M.X.; Breakfield, X.O.; Chiocca, E.A. 1994: Gene therapy for brain tumors: gene therapy for malignant brain tumors using prodrug-sensitivity genes (series 4) No Shinkei Geka. Neurological Surgery 22(12): 1099-1110
Setoguchi, Y.; Tamaki, Y.; Oka, M.; Kira, S. 1996: Transfer of endothelial nitric oxide synthase gene in the purpose of gene therapy for pulmonary arterial hypertension Nihon Rinsho. Japanese Journal of Clinical Medicine 54(2): 369-376